STOCK TITAN

HeartSciences merger vote: 3.48M for, 20,933 against

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

HeartSciences Inc. (HSCS) reported vote totals from its November 19, 2026 special meeting, where 4,041,647 shares, or 76.36% of shares entitled to vote, were represented. The merger proposal received 3,480,989 votes for and 20,933 against; the related Nasdaq proposal received 3,459,400 for and 43,445 against.

The Nasdaq proposal sought approval for up to 35,000,000 additional Class A shares through specified private placements, conversions or exercises, or debt exchanges within one month of closing. Total aggregate consideration was capped at $100,000,000, and the applicable price, conversion rate, or exchange rate was subject to a maximum 20% discount to market price. The reverse-split proposal received 3,981,498 votes for and 40,735 against; it was subject to board discretion and mutual agreement with Fortitude Seller on a ratio from 1-for-2 to 1-for-5. Shareholders also voted on charter changes, including a proposed company name change to Fortitude Mining Group, Inc.

Filing Explained

The special-meeting vote is complete, but proposed class authorizations and voting rights are not themselves an issuance of shares.

The special-meeting vote is complete, but proposed class authorizations and voting rights are not themselves an issuance of shares.

In its November 19, 2026 vote report, HeartSciences records voting on proposed charter changes designating 350,000,000 authorized Class A shares and 150,000,000 authorized Class V shares; these figures describe proposed charter authorization, not shares reported as issued.

Other proposed terms would give Class A holders, voting separately, the sole right to elect one director and would allow qualifying holders to take action by written consent instead of at a meeting.

Item 5.07 Submission of Matters to a Vote of Security Holders Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Common shares outstanding 4,949,283 shares As of October 8, 2026
Shares represented at special meeting 4,041,647 shares (76.36%) Shares entitled to vote, present virtually or by proxy
Votes for, combination proposal 3,480,989 votes Special meeting
Votes for, Nasdaq proposal 3,459,400 votes Special meeting
Maximum additional Class A issuance in proposal 35,000,000 shares Proposed issuance within one month of closing through specified methods
Maximum aggregate consideration $100,000,000 For the proposed additional issuance; cash, Zcash, or satisfaction of indebtedness
Maximum discount to market price 20% Limit for the applicable purchase price, conversion rate, or exchange rate
Proposed reverse split range 1-for-2 through 1-for-5 Ratio subject to board discretion and agreement with Fortitude Seller
Broker Non-Votes regulatory
"536,575 Broker Non-Votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
Class V Common Stock technical
"establish the terms of the Class V Common Stock"
public float financial
"increasing the public float of Class A Common Stock"
Public float is the total number of a company's shares that are available for trading by the general public. It excludes shares held by company insiders or large stakeholders who are unlikely to sell them easily. This figure helps investors understand how much of the company's stock is actively available, which can influence its liquidity and how easily its price might change.
reverse stock split financial
"effect ... a reverse stock split"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
Nasdaq Listing Rules 5635(a), 5635(b) and 5635(d) regulatory
"pursuant to Nasdaq Listing Rules 5635(a), 5635(b) and 5635(d)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were the HSCS special-meeting results for the merger proposal?

It received 3,480,989 votes for and 20,933 against. The combination proposal concerned the Merger Agreement and the transactions contemplated by it; 3,150 shares abstained and 536,575 broker non-votes were recorded.

What additional share issuance did HSCS shareholders vote on?

The Nasdaq proposal sought approval for up to 35,000,000 additional Class A shares through specified private placements, conversions or exercises, or debt exchanges within one month of closing. Total consideration could not exceed $100,000,000 and could be in cash, Zcash, or satisfaction of indebtedness; the applicable price or rate was subject to a maximum 20% discount to market price.

What reverse stock split did HSCS propose?

The proposal sought approval for a 1-for-2 through 1-for-5 reverse split at the board’s discretion, with the ratio to be mutually agreed by HeartSciences and Fortitude Seller. It received 3,981,498 votes for and 40,735 against.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001468492 0001468492 2026-11-19 2026-11-19 0001468492 us-gaap:CommonStockMember 2026-11-19 2026-11-19 0001468492 HSCS:WarrantsMember 2026-11-19 2026-11-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 19, 2026

 

HeartSciences Inc.

(Exact name of Registrant as Specified in Its Charter)

 

Texas   001-41422   26-1344466
(State or Other Jurisdiction
of Incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

  

550 Reserve Street, Suite 360

Southlake, Texas

  76092
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (682) 237-7781

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock   HSCS   The Nasdaq Stock Market LLC
Warrants   HSCSW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

On November 19, 2026, HeartSciences Inc. (the “Company”) held a special meeting of shareholders (the “Special Meeting”). At the Special Meeting, the Company’s shareholders voted on the proposals described below. The proposals presented at the Special Meeting are described in detail in the Company’s definitive proxy statement for the Special Meeting filed with the U.S. Securities and Exchange Commission (the “SEC”) on October 19, 2026 (the “Proxy Statement”), as supplemented by the Company’s Current Report on Form 8-K filed by the Company on November 6, 2026 and the Company’s definitive additional materials on Schedule 14A filed by the Company on November 10, 2026 relating to the Proxy Statement. Capitalized terms used but not otherwise defined herein have the meanings given to them in the Proxy Statement.

 

Of the 4,949,283 shares of the Company’s common stock, $0.001 par value per share (the “common stock”), outstanding and 343,516 shares of common stock issuable upon the conversion of 380,440 shares of Series C Convertible Preferred Stock, $0.001 par value per share (the “Series C Preferred Stock”), outstanding, each as of October 8, 2026 (the “Record Date”) and entitled to vote at the Special Meeting, 4,041,647, or 76.36%, of the shares entitled to vote were present virtually or by proxy. Accordingly, a quorum was present at the Special Meeting.

 

The results for each of the proposals submitted to a vote of shareholders at the Special Meeting are as follows:

  

Proposal 1: The Combination Proposal

 

The Company’s shareholders voted as follows with respect to the proposal to approve the Agreement and Plan of Merger (as amended on July 27, 2026 and as it may be further amended from time to time, the “Merger Agreement”) and the transactions contemplated therein (collectively, the “Transactions”) pursuant to the Texas Business Organizations Code:

 

For   Against   Abstained   Broker Non-Votes 
 3,480,989    20,933    3,150    536,575 

 

Proposal 2: The Nasdaq Proposal

 

The Company’s shareholders voted as follows with respect to the proposal to approve (a) the issuance of shares of Class V Common Stock as contemplated by the Merger Agreement, (b) the issuance of shares of Class A Common Stock as contemplated by the Merger Agreement, (c) for the purpose of raising additional cash for the Combined Company and/or increasing the public float of Class A Common Stock, the additional issuance of up to an aggregate of 35,000,000 shares of Class A Common Stock issued (i) in one or more private placements of Class A Common Stock completed within one month of the Closing, (ii) pursuant to the conversion or exercise of debt or equity securities issued by the Company, Fortitude or Fortitude HoldCo in one or more private placements completed within one month of the Closing and which securities are convertible into or exercisable for Class A Common Stock, and/or (iii) pursuant to the exchange of indebtedness of the Company, Fortitude or Fortitude HoldCo that is outstanding prior to the Closing into Class A Common Stock in a private transaction completed within one month of the Closing, with total aggregate consideration, in the form of cash, Zcash or the satisfaction of indebtedness, not to exceed $100,000,000, and with such purchase price, conversion rate or exchange rate, as applicable, subject to a maximum discount of 20% to the market price of the common stock, and (d) the change of control of the Company resulting from the Transactions, pursuant to Nasdaq Listing Rules 5635(a), 5635(b) and 5635(d):

 

For   Against   Abstained   Broker Non-Votes 
 3,459,400    43,445    2,228    536,574 

 

Proposals 3A-G: The Charter Adoption Proposals

 

The Company’s shareholders voted on the following proposals to approve and adopt the amendments to the Amended and Restated Certificate of Formation of the Company set forth in the Second Amended and Restated Certificate of Formation of the Company, the form of which was attached to the Proxy Statement as Annex B:

 

Proposal 3A

 

The Company’s shareholders voted as follows with respect to Proposal 3A, to change the name of the Company to “Fortitude Mining Group, Inc.”:

 

For   Against   Abstained 
 3,987,307    39,842    14,496 

 

1

 

Proposal 3B

 

The Company’s shareholders voted as follows with respect to Proposal 3B, to change the par value of the authorized common stock of the Company to $0.0001 par value per share:

 

For   Against   Abstained 
 3,958,686    61,217    21,742 

 

Proposal 3C

 

The Company’s shareholders voted as follows with respect to Proposal 3C, to designate the Company’s existing class of common stock as “Class A Common Stock” and designate 350,000,000 shares of the Company’s authorized common stock as Class A Common Stock:

 

For   Against   Abstained   Broker Non-Votes 
 3,457,519    35,872    11,682    536,574 

 

Proposal 3D

 

The Company’s shareholders voted as follows with respect to Proposal 3D, to establish the terms of the Class V Common Stock and designate 150,000,000 shares of the Company’s authorized common stock as Class V Common Stock:

 

For   Against   Abstained   Broker Non-Votes 
 3,377,858    42,552    84,662    536,575 

 

Proposal 3E

 

The Company’s shareholders voted as follows with respect to Proposal 3E, to grant the holders of Class A Common Stock the sole right, voting separately as a single class, to elect one director, designated by the board of directors of the Company as the “Class A Director”:

 

For   Against   Abstained   Broker Non-Votes 
 3,476,116    16,190    12,767    536,574 

 

Proposal 3F

 

The Company’s shareholders voted as follows with respect to Proposal 3F, to allow holders representing not less than the minimum number of shares of Combined Company Common Stock (which are issued, outstanding and entitled to vote) that would be necessary to authorize or take any action at a meeting of shareholders to take such action by written consent in lieu of a meeting:

 

For   Against   Abstained   Broker Non-Votes 
 3,363,152    134,855    7,067    536,573 

 

2

 

Proposal 3G

 

The Company’s shareholders voted as follows with respect to Proposal 3G, to provide for certain other changes in connection with the amendment and restatement of the Amended and Restated Certificate of Formation of the Company:

 

For   Against   Abstained   Broker Non-Votes 
 3,354,309    135,135    15,630    536,573 

 

Proposal 4: The Reverse Stock Split Proposal

 

The Company’s shareholders voted as follows with respect to the proposal to approve an amendment to the Amended and Restated Certificate of Formation of the Company to effect, at the discretion of the Company’s board of directors (the “Board”), a reverse stock split of the issued and outstanding common stock at a ratio to be determined by the Board and mutually agreed to by the Company and Fortitude Seller, within a range of one-for-two through one-for-five, inclusive, in the form attached to the Proxy Statement as Annex H:

 

For   Against   Abstained 
 3,981,498    40,735    19,411 

 

Proposal 5: The Plan Amendment Proposal

 

The Company’s shareholders voted as follows with respect to the proposal to approve the amendment and restatement of the Company’s equity incentive plan, in the form attached to the Proxy Statement as Annex C:

 

For   Against   Abstained   Broker Non-Votes 
 3,207,036    281,504    16,532    536,575 

 

Proposal 6: The Adjournment Proposal

 

The Company’s shareholders voted as follows with respect to the proposal to approve the adjournment of the Special Meeting, if necessary, if a quorum is present, to solicit additional proxies if there are not sufficient votes at the time of the Special Meeting to approve any of the Proposals presented for a vote at the Special Meeting.

 

For   Against   Abstained 
 3,930,880    103,579    7,184 

 

No other matters were considered or voted upon at the Special Meeting.

 

3

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  HEARTSCIENCES INC.
     
Date: November 19, 2026 By: /s/ Andrew Simpson
  Name:  Andrew Simpson
  Title: President, Chief Executive Officer, and
    Chairman of the Board of Directors

 

4

 

Filing Exhibits & Attachments

4 documents

Keep reading